SHORT MINI FUTURE WARRANT - ROCHE GS Stock

Certificat

DE000GK14GK8

Real-time BOERSE MUENCHEN 14:26:21 2024-05-21 EDT
17.4 EUR +0.46% Intraday chart for SHORT MINI FUTURE WARRANT - ROCHE GS
Current month-9.27%
1 month-10.26%
Date Price Change
24-05-21 17.4 +0.46%
24-05-17 17.32 -1.09%
24-05-16 17.51 -4.68%
24-05-15 18.37 -2.03%
24-05-14 18.75 +1.68%

Real-time BOERSE MUENCHEN

Last update May 21, 2024 at 02:26 pm

More quotes

Static data

Product typeKnock-Out with Stop Loss
Buy / SellPUT
Underlying ROCHE HOLDING AG
Issuer Goldman Sachs
WKN GK14GK
ISINDE000GK14GK8
Date issued 2022-03-07
Strike 407.5 CHF
Maturity Unlimited
Parity 10 : 1
Emission price 11.13
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 20.6
Lowest since issue 3.46

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
234.4 CHF
Average target price
279.4 CHF
Spread / Average Target
+19.19%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW